Business
Scancell: Response to Press Speculation
Scancell Holdings plc is in advanced discussions for a potential reverse merger with Neuphoria Therapeutics Inc. through an all-share transaction, which could facilitate a Nasdaq listing and increase its profile with US specialist investors. Concurrently, Scancell is exploring equity and debt financing to support a global Phase 3 registrational study for its lead asset, iSCIB1+. The outcome of these discussions and financing remains uncertain, and further announcements will be made as appropriate. Disclaimer*
About this update from Scancell Holdings Plc
26 June 2026 Scancell Holdings plc Scancell: Response to Press Speculation Scancell Holdings plc (AIM: SCLP) ("Scancell" or the "Company"), the developer of active immunotherapies to treat cancer, notes recent press speculation and confirms it is in advanced discussions with Neuphoria Therapeutics Inc. ("Neuphoria") regarding a potential reverse merger transaction, whereby Scancell would acquire Neuphoria via an all-share transaction. The potential reverse merger could facilitate a Nasdaq listing for Scancell, which the Company believes could increase its profile with US specialist investors. Concurrently, Scancell is in discussions regarding possible equity and debt financing to support a planned global Phase 3 registrational study for its lead asset, iSCIB1+. The potential acquisition and associated financing remain subject to inter alia final terms and definitive documentation. There can be no certainty that firm agreement between Scancell and Neuphoria will be reached nor certainty over the quantum and terms of associated financing. It is not anticipated that the potential transaction would constitute a reverse takeover for the purpose of the AIM Rules for Companies. Further announcements will be made, as appropriate, in due course. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR) as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018. The person responsible for arranging for the release of this announcement on behalf of Scancell is Phillip L'Huiller, Chief Executive Officer. -ENDS- Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage biotechnology company developing targeted off-the-shelf novel immunotherapies, to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, the lead product from their DNA ImmunoBody® platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in a Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope® platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, Scancell's wholly owned subsidiary, GlyMab Therapeutics L...
View stock analysis, news, and events for Scancell Holdings Plc